RxDoctor Payments Data

Melissa Hunt

Family · Terre Haute, INNPI 1275190845

Payments from drug & device makers

$1,652in general payments, 2019–2025

Across 71 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$635
  • Pfizer$239
  • Boston Scientific$138
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$104
  • Radius Health, Inc.$79
  • Collegium Pharmaceutical, Inc.$75
  • plus $382 from 13 others

What the payments were for

  • Food & beverage$1,652100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,652 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$208,811
Medicare patients
383
Services billed
2,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$38,977
XifaxanRifaximin11$34,991
JardianceEmpagliflozin92$28,085
RybelsusSemaglutide23$23,783
Fiasp FlextouchInsulin Aspart (Niacinamide)49$14,844
MyrbetriqMirabegron61$14,083
TrulicityDulaglutide13$12,999
TradjentaLinagliptin45$11,636
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog96$9,316
Demeclocycline Hcl13$8,867
Memantine Hcl80$8,623
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,234
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc67$6,986
LinzessLinaclotide11$6,866
Galantamine Hbr77$6,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$239$38,977128 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$104$34,99111 claims
Lilly USA, LLCTrulicity$33$12,99913 claims
AbbVieLinzess$635$6,86611 claims
GSKBreo Ellipta$13$4,70511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →